决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:The promise of immunotherapy for central nervous system tumours.
神经系统和免疫系统通过双向交互作用紧密相连。
神经系统和免疫系统通过双向交互作用紧密相连。鉴于侵袭性和难治性中枢神经系统(CNS)肿瘤的治疗选择有限,免疫疗法正日益被探索作为这些恶性肿瘤的潜在治疗方法。在本综述中,我们概述了为使用免疫疗法治疗CNS肿瘤提供基础的神经系统-免疫系统联系。然后,我们总结了使用免疫疗法(包括CAR-T 细胞疗法、溶瘤病毒、癌症疫苗和免疫检查点抑制剂)治疗原发性CNS癌症(如高级别胶质瘤、难治性胚胎性脑肿瘤和原发性CNS淋巴瘤)的临床前和临床研究结果。最后,我们回顾了这些免疫治疗方法可能引起的神经系统症状和综合征。
The nervous and immune systems are intricately linked to one another through bi-directional crosstalk. Given the limited therapeutic options for aggressive and refractory central nervous system (CNS) tumours, immunotherapies are increasingly being explored as potential treatments for these malignancies. In this Review, we provide an overview of the nervous system-immune system connections that provide the basis for the use of immunotherapy to treat CNS tumours. We then summarize the outcomes from preclinical and clinical studies that have used immunotherapies, including chimeric antigen receptor T cell therapy, oncolytic viruses, cancer vaccines and immune-checkpoint inhibitors, for the treatment of primary CNS cancers such as high-grade gliomas, refractory embryonal brain tumours and primary CNS lymphomas. Finally, we review the neurological symptoms and syndromes that can arise with these immunotherapeutic approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。